Rezolute, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2024 (the company’s fiscal third quarter; the request metadata’s “2023 Q3” does not match the filing). The filing was signed May 15, 2024. Rezolute is a clinical-stage biopharmaceutical company developing RZ358 for hyperinsulinism and RZ402 for diabetic macular edema (DME).
Financial results and liquidity
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | None in 2024 or 2023 | None in 2024 or 2023 |
| Research and development expense | $12.4 million vs. $14.2 million | $36.7 million vs. $32.9 million |
| General and administrative expense | $3.8 million vs. $2.9 million | $10.7 million vs. $8.9 million |
| Net loss | $17.1 million vs. $15.7 million | $45.5 million vs. $39.1 million |
| Net loss per share, basic and diluted | $0.34 vs. $0.30 | $0.89 vs. $0.76 |
| Cash used in operating activities | Not presented for the quarter | $38.8 million vs. $33.1 million |
There is no meaningful revenue or operating margin to report. At March 31, 2024, cash and cash equivalents were $5.9 million and marketable debt securities totaled $75.7 million ($74.1 million short-term and $1.6 million long-term). Working capital was approximately $75.3 million; total liabilities were $16.9 million and shareholders’ equity was $70.9 million. The filing reports no outstanding borrowings; the company repaid and terminated its prior loan in 2022. Cash, cash equivalents and investments declined from $118.4 million at June 30, 2023 to $81.6 million at March 31, 2024.
Changes versus the prior comparable periods
- For the quarter, R&D expense declined 13%, mainly because the prior-year period included a $3.0 million ActiveSite milestone. Higher RZ402 clinical costs and R&D compensation partly offset that decrease. G&A expense rose 31%, primarily due to compensation-related costs.
- For the nine months, R&D expense increased 11%, reflecting RZ358 Phase 3 preparation, manufacturing and preclinical work, studies addressing the FDA partial clinical holds, and RZ402 Phase 2 activity. G&A expense increased 20%, including higher professional fees and compensation.
- Nine-month operating cash use increased $5.7 million year over year. Investment maturities and purchases produced $29.0 million of net investing cash inflow, compared with $95.1 million used in investing activities in the prior-year period. The company received no financing proceeds in the current nine-month period.
- Quarterly non-operating results included a $2.0 million loss from remeasurement of the Exchange PFW derivative liability. Nine-month interest and other income rose to $3.8 million from $2.7 million, but quarterly interest income fell to $1.1 million from $1.5 million as invested funds declined.
Outlook, developments and risks
- Management said existing cash and investments should fund contractual obligations and planned activities at least through the third quarter of calendar 2025. The liquidity note separately says resources are expected to cover ongoing activities through May 2025, at a minimum. Management warns that additional financing will be required for all long-term capital needs; even a fully utilized $50 million at-the-market (ATM) program would not cover them. No ATM shares had been sold by March 31, 2024.
- RZ358: The global Phase 3 sunRIZE study is intended to enroll approximately 56 participants, with enrollment targeted by calendar year-end 2024 and topline results expected in mid-2025. The FDA’s partial clinical holds restrict U.S. participation, including dosing participants under 12 and dosing above 3 mg/kg. The company plans to submit additional nonclinical evidence to seek modification of the holds but cautions there is no assurance the FDA will do so. The filing reports that a $5.0 million XOMA milestone was incurred and paid after quarter-end upon first-patient dosing in the Phase 3 study; another $5.0 million is due upon last-patient dosing, expected within 12 months, subject to timing uncertainty.
- RZ402: The Phase 2 DME study completed dosing 94 participants; topline results were expected in May 2024. The filing describes this as a planned announcement, not a reported result.
- Management described favorable compassionate-use experience with RZ358 in tumor-related hyperinsulinism and said the FDA acknowledged the unmet need and potential benefit at a pre-IND meeting. A registrational program remains under evaluation; management said resources are not currently available to support another late-stage study.
- The March 2024 exchange of 3.0 million common shares for pre-funded warrants reduced outstanding common shares, but the warrants were recorded as a $7.6 million derivative liability at quarter-end, generating a $2.0 million non-cash loss. A May 13, 2024 amendment supported equity classification; the company expects reclassification to equity in the June quarter and reported an additional $0.9 million fair-value loss after quarter-end through May 13.
- Management identified a material weakness in internal control over financial reporting involving accounting for the Exchange PFWs. Disclosure controls were deemed ineffective at the reasonable-assurance level as of March 31, 2024. The company plans to use additional third-party specialists but cannot assure the weakness will be remediated.
- The company has an accumulated deficit of $306.5 million, has never generated meaningful revenue, and expects ongoing operating losses and a need for future financing. Investment holdings are exposed to interest-rate and credit risks. No material pending or threatened litigation was reported; the filing states no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Actual RZ402 Phase 2 topline results and whether the expected May 2024 announcement occurred.
- SunRIZE enrollment and dosing status, including the filing’s statement that no patients were enrolled as of March 31 versus the subsequent disclosure that first-patient dosing triggered the XOMA milestone.
- FDA decisions on the RZ358 partial clinical holds and the timing and outcome of the company’s planned submission.
- Cash burn, investment maturities, the differing stated runway horizons, and the timing of the $5.0 million XOMA milestone due upon last-patient dosing.
- Whether the ATM is used, the amount and terms of any additional financing, and the resulting dilution.
- Completion of the Exchange PFW equity reclassification and remediation of the disclosed material weakness; also verify the share count and potential dilution from outstanding warrants and options.